Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed at developing a blood-based diagnostic test based on the company’s Aβ42CC technology.</li><li>While this represents a somewhat unexpected commercial route, we view the initiative as strategically and scientifically well-motivated.</li><li>If successful, the project could open an additional path to commercialization and strengthen the long-term value proposition of ALZ-101 through companion diagnostic opportunities.</li></ul>

Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed at developing a blood-based diagnostic test based on the company’s Aβ42CC technology.While this represents a somewhat unexpected commercial route, we view the initiative as strategically and scientifically well-motivated.If successful, the project could open an additional path to commercialization and strengthen the long-term value proposition of ALZ-101 through companion diagnostic opportunities.

Alzinova: Collaboration to develop innovative diagnostic test